文献速递乳腺MR

乳腺多参数MRI预测乳腺癌新辅助化疗反应的BMMR2挑战赛

Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 Challenge.
PubMed 文献 · Radiol Imaging Cancer · 2024-01-01

BMMR2计算挑战赛于2021年5月28日至12月21日举行,基于I-SPY 2/ACRIN 6698试验中191例女性的573次乳腺MRI,评估多参数MRI(含DWI与DCE)结合临床数据预测新辅助治疗后病理完全缓解的性能。8支团队提交最终预测,其中3支团队的AUC点估计值高于基准AUC 0.782(95%CI 0.670–0.893),分别为0.803(95%CI 0.702–0.904)、0.838(95%CI 0.748–0.928)和0.840(95%CI 0.748–0.932)。挑战赛识别出多个高预测性能模型,可能进一步拓展多参数乳腺MRI作为治疗反应早期标志物的价值。

要点

  • 挑战赛数据来自I-SPY 2/ACRIN 6698试验的573次乳腺MRI(191例女性),训练集60%、测试集40%。
  • 基准AUC为0.782(95%CI 0.670–0.893),3支团队AUC点估计值高于基准,最高0.840。
  • 参赛方法涵盖从提取个体特征到深度学习与人工智能,纳入DCE和DWI单独或联合使用。

核心结论

  • BMMR2挑战赛识别出多个高预测性能模型,可能进一步拓展多参数乳腺MRI作为治疗反应早期标志物的价值。

研究设计与样本

  • 计算挑战赛,于2021年5月28日开放、2021年12月21日关闭;数据为I-SPY 2/ACRIN 6698试验(ClinicalTrials.gov: NCT01042379)中191例女性(平均年龄48.9岁±10.56)的573次乳腺MRI研究;挑战队列分为训练集(60%)和测试集(40%),参赛团队对测试集pCR结果设盲;预测性能以AUC评估,并与ACRIN 6698主要分析建立的基准比较。

诊断标准与关键数值

  • 采用受试者工作特征曲线下面积(AUC)评估预测性能;基准AUC为0.782(95%CI 0.670–0.893);8支团队提交最终预测,其中3支团队AUC点估计值高于基准,分别为0.803(95%CI 0.702–0.904)、0.838(95%CI 0.748–0.928)和0.840(95%CI 0.748–0.932)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To describe the design, conduct, and results of the Breast Multiparametric MRI for prediction of neoadjuvant chemotherapy Response (BMMR2) challenge. Materials and Methods The BMMR2 computational challenge opened on May 28, 2021, and closed on December 21, 2021. The goal of the challenge was to identify image-based markers derived from multiparametric breast MRI, including diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) MRI, along with clinical data for predicting pathologic complete response (pCR) following neoadjuvant treatment. Data included 573 breast MRI studies from 191 women (mean age [±SD], 48.9 years ± 10.56) in the I-SPY 2/American College of Radiology Imaging Network (ACRIN) 6698 trial (ClinicalTrials.gov: NCT01042379). The challenge cohort was split into training (60%) and test (40%) sets, with teams blinded to test set pCR outcomes. Prediction performance was evaluated by area under the receiver operating characteristic curve (AUC) and compared with the benchmark established from the ACRIN 6698 primary analysis. Results Eight teams submitted final predictions. Entries from three teams had point estimators of AUC that were higher than the benchmark performance (AUC, 0.782 [95% CI: 0.670, 0.893], with AUCs of 0.803 [95% CI: 0.702, 0.904], 0.838 [95% CI: 0.748, 0.928], and 0.840 [95% CI: 0.748, 0.932]). A variety of approaches were used, ranging from extraction of individual features to deep learning and artificial intelligence methods, incorporating DCE and DWI alone or in combination. Conclusion The BMMR2 challenge identified several models with high predictive performance, which may further expand the value of multiparametric breast MRI as an early marker of treatment response. Clinical trial registration no. NCT01042379 Keywords: MRI, Breast, Tumor Response Supplemental material is available for this article. © RSNA, 2024.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Li W, Partridge SC, Newitt DC, et al. Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 Challenge. Radiol Imaging Cancer. 2024. PMID: 38180338. doi:10.1148/rycan.230033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。